Anavex Life Sciences Corp. (AVXL:NASDAQ) closed at $1.26 on October 19, 2026, down 3.86% on the day. The stock trades 86.7% below its 52-week high of $9.50 and 0.8% above its 52-week low of $1.25. Over the past year, it lost 85.4%. Anavex Life Sciences Corp. is part of the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -13.25% | -45.64% | -45.87% | -64.11% | -85.41% |
In 252 trading sessions since October 16, 2025, AVXL closed higher on 112 days (44%). Its best day was December 3, 2025 (+24.52%) and its worst was November 14, 2025 (-35.94%). The stock moved 10% or more in a single session 11 times.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers. The company's lead drug candidates include ANAVEX 2-73, a Phase 2a clinical trial for the treatment of Alzheimer's disease; and preclinical stage to treat Parkinson's disease. Its preclinical drug candidates include ANAVEX 3-71, which uses ligands that activate sigma-1 and M1 muscarinic receptors to treat Alzheimer's disease; ANAVEX 1-41, a sigma-1 agonist that protects nerve cells from degeneration or death; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain. The company was founded in 2006 and is based in New York, New York.
Find more stocks like AVXL with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.